Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Metrion Biosciences (“Metrion”) and is pleased to announce the placement of Lee Patterson, as Chief Executive Officer (CEO). He succeeds Dr Andrew Southan, who has stepped down after five years in the post.

Metrion Biosciences is a preclinical drug discovery CRO and drug discovery business specializing in ion channel assays. The Company offers a range of services including industry-leading cardiac safety assays, high-throughput screening, and translational research for neurological and cardiotoxicity testing.

A seasoned life sciences and CRO executive with a proven track record in driving growth and implementing effective strategies, Lee Patterson will guide the Company as it seeks to execute an ambitious growth strategy, enhancing its specialist services and expanding further in key global markets. He brings extensive experience in leading preclinical CROs, including his recent role as CEO of Charnwood Discovery, where he successfully oversaw its acquisition by Concept Life Sciences. Lee's expertise in navigating complex business landscapes and delivering exceptional results will be instrumental in propelling the Company forward.

Commenting on the search work with Coulter Partners, Keith McCullagh, Chairman, Metrion Biosciences said: “We were impressed with Coulter Partners' deep understanding of our industry and their skill in identifying and attracting top-tier candidates who could contribute significantly to our company's future. Their expertise is invaluable for organizations seeking top talent.”

Lee Patterson, CEO, Metrion Biosciences, commented: “Metrion Biosciences has built an impressive reputation in ion channel drug discovery, with proven commitment to outstanding customer service and world class science. I am excited to join this talented team and look forward to working with them to enhance and expand our specialized services to meet the needs of our clients worldwide.”

----

Lee Patterson, Chief Executive Officer, Metrion Biosciences

A renowned leader in the sector, Lee specializes in steering preclinical CROs to implement robust and effective plans for long-term commercial growth.

Previously CEO at Charnwood Discovery, a provider of integrated drug discovery services with a global biotech and pharma client base, he led the company through its successful acquisition by Concept Life Sciences in October 2024. Prior to this, Lee served as Chief Operating Officer at Quanticate, a global biometrics CRO, and Chief Operating Officer at Concept Life Sciences. He also held several executive roles at Covance/Labcorp, the most recent being Executive Director, Global Operations and Early Development Management Office.

About Metrion Biosciences

Metrion Biosciences is a specialist preclinical drug discovery contract research organization (CRO) and drug discovery business. The Company provides customers with access to a range of high-quality ion channel assays including an industry leading panel of in vitro cardiac safety assays, high throughput screening, and translational research such as native cell and phenotypic assays for neurological and cardiotoxicity testing. Metrion also provides neuroscience focused assays with brain slices, DRG neurons, and other primary neurons. Metrion’s leadership has extensive and in-depth experience, offering careful interpretation of experimental findings, communicating results and providing strategic recommendations to support decision making to best inform screening strategy. Acting as an extension of our clients’ research teams, Metrion provides tailored assay formats, quality assured data packages and traditional or bespoke and novel studies on a fee-for-service or collaboration basis.

For more information, please visit www.metrionbiosciences.com

About Coulter Partners

We are executive search and leadership development specialists working to build a better future. As advisors and consultants to companies at the cutting edge of Health, Science, and Technology, we are united by our mission to build teams that change the world. Operating uniquely as one global team, we have honed our expertise, platform, and data for over two decades, working across three continents, and in 40 countries. Applying what we learn through our work with boards, leadership teams, and investors in the world’s most innovative companies, we bring together and develop the right people at the right time to propel them to achieve their worthwhile goals.

www.coulterpartners.com

Coulter Partners places seasoned life sciences and CRO leader as CEO of Metrion Biosciences

About Metrion Biosciences

About Coulter Partners

Related

Coulter Partners secures industry-leading Chief Medical Officer for Solu Therapeutics

Coulter Partners strengthens leadership at IMU Biosciences with placements of Chief Executive Officer and Chief Business Officer

Coulter Partners places new Chief Business Officer at the Cell & Gene Therapy Catapult

Coulter Partners places new Chief Executive Officer at ArcticZymes